NovoCure
NVCR
226 hedge funds and large institutions have $1.49B invested in NovoCure in 2023 Q3 according to their latest regulatory filings, with 43 funds opening new positions, 74 increasing their positions, 63 reducing their positions, and 82 closing their positions.
79% more call options, than puts
Call options by funds: $23.8M | Put options by funds: $13.3M
17% more repeat investments, than reductions
Existing positions increased: 74 | Existing positions reduced: 63
0.86% more ownership
Funds ownership: 85.57% → 86.43% (+0.86%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
15% less funds holding
Funds holding: 267 → 226 (-41)
48% less first-time investments, than exits
New positions opened: 43 | Existing positions closed: 82
61% less capital invested
Capital invested by funds: $3.78B → $1.49B (-$2.29B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$72.1M |
| 2 |
Voloridge Investment Management
Jupiter,
Florida
|
+$42.8M |
| 3 |
Two Sigma Advisers
New York
|
+$24.6M |
| 4 |
Two Sigma Investments
New York
|
+$23.5M |
| 5 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
+$22.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$78.5M |
| 2 |
Capital World Investors
Los Angeles,
California
|
-$72.4M |
| 3 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$54.1M |
| 4 |
HIC
Hartline Investment Corp
Winnetka,
Illinois
|
-$13.1M |
| 5 |
State Street
Boston,
Massachusetts
|
-$10.8M |
NVCR Hedge Fund Activity: Q3 2023 in Review
226 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in NovoCure (NVCR) for Q3 2023, worth a combined $1.49B — down 61% from $3.78B a quarter earlier.
Sellers outnumbered buyers: 82 funds closed out of NVCR and 43 opened new positions — a net loss of 39 holders — while 63 trimmed existing stakes and 74 added.
The largest buyer was Deep Track Capital, opening a new position worth an estimated $72.1M. The largest seller was T. Rowe Price Investment Management, exiting entirely with an estimated $78.5M sold.
- 226 institutional investors held NovoCure (NVCR) as of Q3 2023, down from 267 in Q2 2023.
- Funds reported $1.49B of NovoCure stock for Q3 2023, down 61% quarter-over-quarter.
- 43 funds opened new NovoCure positions in Q3 2023 and 82 closed out, a net change of -39 holders.
- The largest NovoCure buyer in Q3 2023 was Deep Track Capital, an estimated $72.1M added.
- The largest NovoCure seller in Q3 2023 was T. Rowe Price Investment Management, an estimated $78.5M sold.
Based on aggregated 13F filings for Q3 2023.